

# Mohamed A Kharfan-Dabaja

## List of Publications by Citations

**Source:**

<https://exaly.com/author-pdf/1146320/mohamed-a-kharfan-dabaja-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

242  
papers

3,664  
citations

33  
h-index

52  
g-index

268  
ext. papers

4,840  
ext. citations

4.3  
avg, IF

5.35  
L-index

#	Paper	IF	Citations
242	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , <b>2016</b> , 127, 938-47	2.2	206
241	A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , <b>2012</b> , 12, 290-9	25.5	192
240	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3141-9	2.2	170
239	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. <i>Therapeutic Advances in Hematology</i> , <b>2019</b> , 10, 2040620719841581	5.7	105
238	Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 1005-13	4.7	101
237	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1826-1838	4.7	89
236	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 235-48	4.5	88
235	A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 937-47	4.7	86
234	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , <b>2012</b> , 97, 1882-9	6.6	72
233	Cytokine Release Syndrome: Current Perspectives. <i>ImmunoTargets and Therapy</i> , <b>2019</b> , 8, 43-52	9	71
232	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 2117-2125	4.7	70
231	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2305-2321	4.7	68
230	Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1677-86	4.7	68
229	Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1006-12	4.7	62
228	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1868-1880	4.4	55
227	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1245-1253	13.4	53
226	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e76-e85	4.7	53

225	The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , <b>2020</b> ,	2.7	51
224	Improved survival after acute graft--host disease diagnosis in the modern era. <i>Haematologica</i> , <b>2017</b> , 102, 958-966	6.6	50
223	Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 1006-9	7.1	50
222	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , <b>2019</b> , 3, 1826-1836	7.8	50
221	R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 534-544	4.5	48
220	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1864-71	2.2	46
219	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 2091-2099	4.7	45
218	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. <i>Journal of Hematology and Oncology</i> , <b>2010</b> , 3, 36	22.4	40
217	Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 916-920	4.5	40
216	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 781-789	4.5	36
215	Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. <i>International Journal of Hematology</i> , <b>2010</b> , 91, 124-7	2.3	35
214	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , <b>2019</b> , 33, 2767-2778	10.7	34
213	Allotransplantation for patients age $\geq$ 40 years with non-Hodgkin lymphoma: encouraging progression-free survival. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 960-8	4.7	34
212	Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 507-11	2	34
211	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2020</b> , 105, 1507-1516	6.6	34
210	Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. <i>Immunotherapy</i> , <b>2013</b> , 5, 457-66	3.8	33
209	Rituximab for prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , <b>2011</b> , 93, 578-585	2.3	33
208	Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 315-25	4.5	30

207	Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 1505-11	4.7	30
206	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. <i>Cancer Control</i> , <b>2011</b> , 18, 237-45	2.2	30
205	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. <i>JAMA Oncology</i> , <b>2019</b> , 5, 715-722	13.4	30
204	Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. <i>Cancer</i> , <b>2008</b> , 113, 897-906	6.4	29
203	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , <b>2017</b> , 102, 948-957	6.6	28
202	Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. <i>The Cochrane Library</i> , <b>2011</b> , CD008818	5.2	28
201	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> ,	4.7	27
200	Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 656-61	4.7	25
199	Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. <i>Cancer Control</i> , <b>2012</b> , 19, 68-75	2.2	25
198	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1254-1265	4.4	25
197	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , <b>2020</b> , 4, 1965-1973	7.3	23
196	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 802-14	4.7	23
195	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , <b>2018</b> , 2, 933-940	7.8	23
194	Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. <i>The Cochrane Library</i> , <b>2014</b> , CD010280	5.2	22
193	Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. <i>Annals of Transplantation</i> , <b>2010</b> , 15, 21-9	1.4	22
192	Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. <i>Biology of Blood and Marrow Transplantation</i> , <b>2007</b> , 13, 373-85	4.7	21
191	Granulocytic sarcoma presenting with malignant anasarca in a patient with secondary acute myeloid leukemia. <i>International Journal of Hematology</i> , <b>2004</b> , 79, 250-2	2.3	20
190	Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1094-1106	4.4	20

189	IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 531-539	6.6	20
188	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1011-1018	13.4	19
187	Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 384-93	4.7	18
186	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 117	22.4	17
185	Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 703-709.e1	2	17
184	Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 776-80	4.7	17
183	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1518-1526	2.2	16
182	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. <i>Haematologica</i> , <b>2015</b> , 100, 970-7	6.6	16
181	Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1347-54	4.7	16
180	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , <b>2020</b> , 126, 5077-5087	6.4	16
179	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. <i>Immunotherapy</i> , <b>2016</b> , 8, 435-47	3.8	15
178	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 6	22.4	15
177	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , <b>2020</b> , 34, 3338-3347	10.7	15
176	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1459-1468	14.7	14
175	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 270-278	4.7	14
174	Clotrimazole troches induce suprathreshold blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2016</b> , 9, 157-161	2.7	13
173	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. <i>International Journal of Hematology</i> , <b>2011</b> , 93, 206-212	2.3	13
172	Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience. <i>Blood</i> , <b>2015</b> , 126, 2945-2945	2.2	13

171	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, e35-e39	2	12
170	Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. <i>Biology of Blood and Marrow Transplantation</i> , <b>2007</b> , 13, 997-1004	4.7	12
169	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 6-20		12
168	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1695-1700	4.7	11
167	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1525-1532	4.4	11
166	Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. <i>Leukemia Research</i> , <b>2018</b> , 67, 1-5	2.7	11
165	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1087-93	4.7	11
164	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 753-758	2	11
163	Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1074-82	4.7	11
162	Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. <i>Expert Review of Vaccines</i> , <b>2015</b> , 14, 341-50	5.2	11
161	Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. <i>Blood Advances</i> , <b>2020</b> , 4, 3435-3442	7.8	11
160	Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. <i>Future Oncology</i> , <b>2016</b> , 12, 2631-2642	3.6	11
159	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 76-82	4.7	11
158	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 49	7	11
157	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. <i>Leukemia Research</i> , <b>2014</b> , 38, 1165-72	2.7	10
156	Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> , 14, 33-40	2.7	10
155	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , <b>2020</b> , 105, 1329-1338	6.6	9
154	Hematopoietic Cell Transplantation for Richter Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1938-1944	4.7	9

153	A new dawn for gemtuzumab ozogamicin?. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 913-4	21.7	9
152	Reanalysis of TransVax immunogenicity. <i>Lancet Infectious Diseases, The</i> , <b>2013</b> , 13, 18	25.5	9
151	Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. <i>Blood</i> , <b>2021</b> ,	2.2	9
150	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. <i>Cancer</i> , <b>2019</b> , 125, 4417-4425	6.4	8
149	Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1288-300	4.7	8
148	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. <i>Current Research in Translational Medicine</i> , <b>2020</b> , 68, 159-170	3.7	8
147	Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2018</b> , 11, 53-64	2.7	8
146	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. <i>Blood Reviews</i> , <b>2018</b> , 32, 159-166	11.1	8
145	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1137-1143	4.7	7
144	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 573-582	4.5	7
143	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1434-1444	4.4	7
142	Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 309-316	1.9	7
141	Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 949-958	4.7	7
140	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 472-479	4.7	7
139	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2020</b> , 13, 1-6	2.7	7
138	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2330-2337	4.7	6
137	Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2016</b> , 9, 26-9	2.7	6
136	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5143-5155	12.9	6

135	Umbilical cord blood transplantation induces a durable remission in hepatosplenic gamma-delta T cell lymphoma with associated hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 934-5	7.1	6
134	A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. <i>Biomedicines</i> , <b>2017</b> , 5,	4.8	6
133	Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 335-40	2	6
132	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e694-e711	2	6
131	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2139-2146	4.7	6
130	Allogeneic transplantation in elderly patients ≥5 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 97	7	6
129	What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 325-331	4.4	6
128	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. <i>Blood Advances</i> , <b>2021</b> , 5, 3528-3539	7.8	6
127	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , <b>2020</b> , 126, 2279-2287	6.4	6
126	Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. <i>Immunotherapy</i> , <b>2015</b> , 7, 1059-71	3.8	5
125	Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Hematology/Oncology Clinics of North America</i> , <b>2020</b> , 34, 621-629	3.1	5
124	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1784-1802	4.7	5
123	Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 854-862	4.5	5
122	Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2018</b> , 11, 96-98	2.7	5
121	Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2018</b> , 11, 1-12	2.7	5
120	Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 59-68	1.9	5
119	Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?. <i>British Journal of Haematology</i> , <b>2007</b> , 139, 234-42	4.5	5
118	Does Bridging Radiation Therapy Affect the Pattern of Failure After CAR T-cell Therapy in Non-Hodgkin Lymphoma?. <i>Radiotherapy and Oncology</i> , <b>2021</b> ,	5.3	5

117	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , <b>2021</b> , 7, 993-1003	13.4	5
116	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. <i>Best Practice and Research in Clinical Haematology</i> , <b>2016</b> , 29, 54-66	4.2	5
115	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 58-66		5
114	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. <i>Blood Advances</i> , <b>2021</b> , 5, 1154-1163	7.8	5
113	Thymoma with Concomitant Pure Red Cell Aplasia, Good $\text{\textcircled{R}}$ Syndrome and Myasthenia Gravis Responding to Rituximab. <i>Indian Journal of Hematology and Blood Transfusion</i> , <b>2016</b> , 32, 219-22	0.7	4
112	Guadecitabine for AML and MDS: hype or hope?. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1009-1011	21.7	4
111	A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene CiloleuceL in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14). <i>Blood</i> , <b>2019</b> , 134, 4093-4093	2.2	4
110	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 698-707	4.4	4
109	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , <b>2020</b> , 4, 3180-3190	7.8	4
108	Diagnosis and treatment of subcutaneous panniculitis-like T-cell lymphoma: A systematic literature review. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> ,	2.7	4
107	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. <i>International Journal of Hematologic Oncology</i> , <b>2021</b> , 10, IJH33	1	4
106	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 69-78		4
105	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 165.e1-165.e11		4
104	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 110-118		4
103	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 720-728		4
102	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e273-e280	2	3
101	Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations. <i>Immunotherapy</i> , <b>2015</b> , 7, 47-56	3.8	3
100	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 400-405	4.7	3

99	Acute pericarditis and tamponade from Coxsackie B3 in an adult Hematopoietic-Cell-Allograft recipient: A rare but potentially serious complication. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2016</b> , 9, 82-5	2.7	3
98	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 7-13	2	3
97	Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2015</b> , 8, 138-97	3.7	3
96	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1099-1105	4.7	3
95	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2811-2820	1.9	3
94	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 267.e1-267.e5		3
93	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 592-601	4.5	3
92	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , <b>2020</b> , 127, 82-92	6.4	3
91	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 106-112.e1	2	3
90	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 3068-3077	4.4	3
89	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 156	7	3
88	Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , <b>2021</b> ,	7.8	3
87	Hematopoietic cell transplantation: Training challenges and potential opportunities through networking and integration of modern technologies to the practice setting. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2017</b> , 10, 184-188	2.7	2
86	Association Between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 817-819	5.1	2
85	Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.. <i>Blood</i> , <b>2009</b> , 114, 2376-2376	2.2	2
84	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. <i>International Journal of Particle Therapy</i> , <b>2020</b> , 7, 13-20	1.5	2
83	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , <b>2020</b> , 191, 442-452	4.5	2
82	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , <b>2021</b> , 33, 100787	11.3	2

81	Cellular Therapies for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 363-370		2
80	Intraocular involvement of Mantle cell lymphoma: A case report and literature review. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> , 14, 147-152	2.7	2
79	Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 40-48	3.8	2
78	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 486-493	4.7	2
77	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. <i>Blood Advances</i> , <b>2021</b> , 5, 2740-2750	7.8	2
76	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 921.e1-921.e10		2
75	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2911-2921	4.4	2
74	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 757-763	4.5	2
73	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. <i>American Journal of Hematology</i> , <b>2019</b> , 94, E245-E247	7.1	1
72	Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1464-1465	4.4	1
71	Hope for BET inhibition in patients with leukaemia or lymphoma. <i>Lancet Haematology</i> , <b>2016</b> , 3, e157-166	4.6	1
70	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia <b>2019</b> , 185-190		1
69	Granulocytic sarcoma and chronic lymphocytic leukemia of the gastrointestinal tract after allogeneic hematopoietic cell transplantation mimicking graft-versus-host disease. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 350-2	1.9	1
68	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).. <i>Blood</i> , <b>2007</b> , 110, 936-936	2.2	1
67	Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. <i>Blood</i> , <b>2011</b> , 118, 323-323	2.2	1
66	Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis. <i>Blood</i> , <b>2013</b> , 122, 5372-5372	2.2	1
65	TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Blood</i> , <b>2015</b> , 126, 4382-4382	2.2	1
64	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , <b>2021</b> , 138, 2527-2527	2.2	1

63	Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	1
62	Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. <i>Clinical Hematology International</i> , <b>2019</b> , 1, 2-9	1.8	1
61	Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> ,	2.7	1
60	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2108-2117	4.4	1
59	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2194-2202	4.4	1
58	Enteropathy-Associated T cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , <b>2021</b> , 16, 140-147	4.4	1
57	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7522-7522	2.2	1
56	Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 429-432	4.5	1
55	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 167.e1-167.e12		1
54	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> , 14, 141-146	2.7	1
53	Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 548-551	2	1
52	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 911.e1-911.e7		1
51	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 923.e1-923.e12		1
50	Predictors and management of relapse to Axicabtagene Ciloleucel in patients with aggressive B-cell lymphoma. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> ,	2.7	1
49	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-6	1.9	0
48	DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. <i>Blood</i> , <b>2021</b> , 138, 3693-3693	2.2	0
47	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 28, 5-5		0
46	Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. <i>Psychosomatics</i> , <b>2020</b> , 61, 363-370	2.6	0

45	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 28, 48.e1-48.e1		o
44	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 62	7	o
43	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , <b>2022</b> , 12,	7	o
42	Recognizing Risk Factors Associated With Unplanned 30-Day Readmissions in Hematopoietic Cell Transplantation: An Opportunity to Develop Cost-Containment Strategies. <i>JAMA Network Open</i> , <b>2019</b> , 2, e196463	10.4	
41	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , <b>2020</b> , 136, 28-29	2.2	
40	Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant. <i>Blood</i> , <b>2020</b> , 136, 15-15	2.2	
39	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , <b>2020</b> , 136, 42-43	2.2	
38	Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1). <i>Blood</i> , <b>2021</b> , 138, 3910-3910	2.2	
37	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 1750-1750	2.2	
36	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , <b>2021</b> , 138, 1452-1452	2.2	
35	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). <i>Blood</i> , <b>2021</b> , 138, 2285-2285	2.2	
34	A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT). <i>Blood</i> , <b>2021</b> , 138, 3893-3893	2.2	
33	Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 3150-3150	2.2	
32	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , <b>2018</b> , 132, 969-969	2.2	
31	Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. <i>Blood</i> , <b>2018</b> , 132, 4852-4852	2.2	
30	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. <i>Blood</i> , <b>2018</b> , 132, 5873-5873	2.2	
29	Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)? <i>Blood</i> , <b>2019</b> , 134, 785-785	2.2	
28	Efficacy of Allogeneic Hematopoietic Cell Transplantation (HCT) in Sickle Cell Disease: Results of a Systematic Review/Meta-Analysis. <i>Blood</i> , <b>2019</b> , 134, 2106-2106	2.2	

- 27 Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL): a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. *Blood*, **2019**, 134, 3318-3318 2.2
- 26 Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. *Blood*, **2019**, 134, 2588-2588 2.2
- 25 Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. *Blood*, **2019**, 134, 5610-5610 2.2
- 24 The Inpatient Unit in a Cancer Center **2022**, 15-20
- 23 The Infusion Center **2022**, 35-40
- 22 Preparative regimens for lymphoma 57-67
- 21 Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. *Blood*, **2015**, 126, 5524-5524 2.2
- 20 Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. *Blood*, **2015**, 126, 4493-4493 2.2
- 19 Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. *Blood*, **2015**, 126, 4407-4407 2.2
- 18 Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS. *Blood*, **2016**, 128, 3486-3486 2.2
- 17 Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. *Blood*, **2016**, 128, 3551-3551 2.2
- 16 Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC). *Blood*, **2016**, 128, 5824-5824 2.2
- 15 Apheresis of Hematopoietic Progenitor Cell (HPC) From Allogeneic Donors  $\geq 60$  Years of Age. *Blood*, **2009**, 114, 4226-4226 2.2
- 14 Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?.. *Blood*, **2009**, 114, 1022-1022
- 13 Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.. *Blood*, **2009**, 114, 2235-2235 2.2
- 12 Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 2290-2290 2.2
- 11 Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBQR) Using a Novel Principle of CD4-Guided Immune Suppression. *Blood*, **2011**, 118, 3022-3022 2.2
- 10 Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis. *Blood*, **2013**, 122, 1945-1945 2.2

9	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 48-53	3.8
8	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e19501-e19501	2.2
7	Patient perceptions of palliative care in the process of allogeneic hematopoietic cell transplantation.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e24082-e24082	2.2
6	Effect of time to relapse on overall survival (OS) in mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7521-7521	2.2
5	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 7530-7530	2.2
4	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e19552:e19552	
3	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. <i>Lancet Oncology</i> , <b>2016</b> , 17, e1	21.7
2	Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> , 14, 95-103	2.7
1	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR / CMWP of EBMT analysis. <i>British Journal of Haematology</i> ,	4.5